Patel, S., Mckean, M., Piperno-Neumann, S., Shoushtari, A. N., Hernandez-Aya, L., Orloff, M., Khan, S., Montazeri, K., Kapiteijn, E., Buchbinder, E., Agresta, S., Reilly, S., Patriquin, C. M., Hickman, D., Corrigan, D., Granlund, L., Hentemann, M., Piel, J., Martin, P., & Mehmi, I. (2023). 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma. Annals of Oncology, 34, S677–S678. https://doi.org/10.1016/j.annonc.2023.09.2262

Ozturk, D. G., Özkan, H., Akcan, U., & Korkmaz, G. (2023). 23P Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer. ESMO Open, 8(1), 100989. https://doi.org/10.1016/j.esmoop.2023.100989